Completed PHASE3 INTERVENTIONAL 2-arm NCT05813925

A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight

Efficacy and Safety of Cagrilintide S.C. 2.4 mg in Combination With Semaglutide S.C. 2.4 mg (CagriSema S.C. 2.4 mg/2.4 mg) Once-Weekly in East Asian Participants With Overweight or Obesity

Sponsor: Novo Nordisk A/S

Conditions Obesity or Overweight

Interventions Cagrilintide Placebo Semaglutide Semaglutide

Updated 15 times since 2023 Last updated: Jan 15, 2026 Started: Apr 3, 2023 Primary completion: Jan 17, 2025 Completion: Mar 7, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Obesity or Overweight and is currently completed. Novo Nordisk A/S leads this study, which shows 15 recorded versions since 2023 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

15 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE3
Sep 2025 — Feb 2026 [monthly]

Completed PHASE3
May 2025 — Sep 2025 [monthly]

Completed PHASE3
Apr 2025 — May 2025 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Mar 2025 — Apr 2025 [monthly]

Active Not Recruiting PHASE3

▶ Show 10 earlier versions

Jan 2025 — Mar 2025 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Nov 2024 — Jan 2025 [monthly]

Recruiting PHASE3
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Apr 2024 — Jul 2024 [monthly]

Recruiting PHASE3
Feb 2024 — Apr 2024 [monthly]

Recruiting PHASE3
Oct 2023 — Feb 2024 [monthly]

Recruiting PHASE3
Jul 2023 — Oct 2023 [monthly]

Recruiting PHASE3
Jun 2023 — Jul 2023 [monthly]

Recruiting PHASE3
May 2023 — Jun 2023 [monthly]

Recruiting PHASE3

First recorded

Apr 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novo Nordisk A/S

Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aichi, Japan , Bunkyo-ku, Tokyo, Japan , Chiba-shi, Chiba, Japan , Chiyoda-ku, Tokyo, Japan , Chuo-ku, Tokyo, Japan , Gunma, Japan , Ibaraki, Japan , Koriyama-shi, Fukushima, Japan , Miyazaki, Japan , Numakunai, Japan and 8 more locations